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Abstract
Background: Filarial antigen tests are key tools for mapping the distribution of bancroftian filariasis and for detecting
areas with persistent infections following mass drug administration (MDA). A recent study showed that the new Alere
Filariasis Test Strip (FTS) has better analytical sensitivity than the BinaxNOW Filariasis card test (Card Test) for detecting
circulating filarial antigen, and the FTS detected more positive results than the Card Test in a field study performed in a
highly endemic area in Liberia.
Methods: The present study compared the performance of the FTS and the Card Test in community surveys that were
conducted in southern Sri Lanka and in Indonesia (Central Java) in areas with low-level persistence of LF following
multiple rounds of MDA with diethylcarbamazine plus albendazole. The studies were performed in densely populated
semi-urban areas where Wuchereria bancrofti is transmitted by Culex quinquefasciatus.
Results: Antigenemia rates by FTS were 138 % higher in the Sri Lanka study (43/852 vs. 18/852) and 21 % higher in the
Indonesia study (50/778 vs. 41/778) than antigenemia rates by Card Test. Antigenemia rates were significantly higher in
males than in females and higher in adults than in children in both study sites. Although overall antigenemia rates and
test scores were significantly higher by FTS than by Card Test in both study areas, rates in young children were similar
with both tests in both areas.
Conclusions: These results extend the previously reported superior sensitivity of the FTS to areas with low residual
infection rates following MDA, and this could affect mapping and post-MDA survey results in adults. However,
our findings suggest that results of transmission assessment surveys (TAS) performed in school-aged children
are likely to be similar with both tests.
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Background
Lymphatic filariasis (LF) is a major neglected tropical
disease (NTD) that the World Health Organization
(WHO) has targeted for elimination by the year 2020
[1]. The Global Programme to Eliminate Lymphatic
Filariasis (GPELF) recommends repeated rounds of mass
drug administration (MDA) with antifilarial medications
to interrupt transmission of the nematode worms that
cause LF. Almost 5 billion treatment doses of these drugs
were distributed in 60 disease-endemic countries between
the years 2000 and 2012 [2]. WHO guidelines rely heavily
on diagnostic test results to manage different phases of LF
elimination programs. Prior studies have shown that tests
that detect circulating filarial antigen-(CFA) are much
more convenient and more sensitive for detecting Wucher-
eria bancrofti infections than the traditional method of de-
tecting microfilariae (Mf) in night blood samples by
microscopy [3, 4]. For this reason, WHO guidelines recom-
mend CFA tests as a primary tool for mapping the distri-
bution of the infection. In addition, CFA tests are used in
transmission assessment surveys (TAS) that systematically
sample young school-aged children to detect recent infec-
tions [5, 6]. TAS results figure prominently in surveys
based on WHO guidelines for stopping MDA and (later)
for verification of elimination [7–9].
The first field-friendly test for CFA (the ICT Filariasis
Test, produced by ICT Diagnostics, Balgowah, NSW,
Australia) was marketed in 1997 [10]. This test was
transferred to Binax, Inc. (Portland, ME) in 2000, and as
the Binax Now Filariasis card test (Card Test), it has
been widely used by LF elimination programs for map-
ping and post-MDA surveillance. Alere Scarborough (a
successor company to Binax) has recently introduced a
next generation CFA test called the Alere Filariasis Test
Strip (FTS). This immunochromatography test uses the
same reagents as the Card Test on a different platform.
The FTS is less expensive than the Card Test, and it has
a much longer shelf life. A laboratory evaluation showed
that the FTS has a lower limit of detection than the Card
Test, and it detected 27 % more positive results than the
Card Test in a field study that was performed in a high
endemicity setting in Liberia [11]. Despite these advan-
tages, more information is needed from different settings
before the new test can be endorsed as a substitute
for the Card Test. In particular, some experts have
expressed concern that a more sensitive CFA test might
significantly raise the bar for elimination if it detected
many more infections in children than the Card Test
during TAS. Therefore, the purpose of the present study
was to compare the performance of the FTS and the
Card Test in two areas in Asia that have low residual W.
bancrofti infection rates and infection intensities follow-
ing multiple rounds of MDA with diethylcarbamazine
plus albendazole. The studies were performed in densely
populated semi-urban areas where W. bancrofti is trans-
mitted by C. quinquefasciatus.
Methods
Antigen detection tests and protocol
BinaxNOW® Filariasis card tests were purchased from
Alere Scarborough, Inc., Scarborough, ME, USA. Alere
Filariasis Test Strips (FTS) from the same manufacturer
were provided for this study by the company at no cost.
Site specific study protocols and standard operating pro-
cedures for the study were developed by Washington
University investigators in consultation with collaborat-
ing scientists in Sri Lanka and Indonesia.
Ethical approval
The human studies protocols were approved by an eth-
ical review committee at the University of Ruhuna (Galle,
Sri Lanka), and by institutional review boards at the
University of Indonesia, and Washington University School
of Medicine. All adult participants in the study provided
written informed consent. Participation of minors required
their assent and written consent from one parent.
Field studies using the filarial antigen tests
Sri Lanka: study areas and subjects
The studies were performed in two Grama Niladhari (GN)
divisions, Matotagama in Matara district and Unawatuna-
West in Galle district. Matotagama received 12 semian-
nual rounds of mass drug administration for LF with
diethylcarbamazine (DEC) plus albendazole in 2002–2006,
while Unawatuna received 5 rounds of MDA during
that period [12, 13]. These GN divisions were chosen
for this study, because post-MDA surveillance studies
documented low-level persistence of LF [8, 13].
Household maps were prepared for each GN division
by project personnel prior to the surveys. The total
registered populations were 1,561 in Matotagama and
745 in Unawatuna-West. Previous post-MDA surveys
(ages ≥ 2) in these two GN divisions found CFA rates
by Card Test of 3.7 % in Unawatuna West and 4 %
in Matotagama.
The surveys were conducted in January-April 2014 by
three blood collection teams comprised of one medical
officer (team leader/phlebotomist), one field assistant,
and two test readers. CFA tests were performed in
the field at the time of blood collection. The study
surveyed 5 neighborhood clusters in each GN that
were selected based on ease of access and results of
past LF surveys. All households in these clusters
were visited, and persons over 5 years of age were
invited to participate in the study. The mean number
of persons tested per household was 3.1, SD = 1.4
(range 1–9). All persons with positive CFA tests were
treated with a single oral dose of DEC 6 mg/kg plus
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albendazole 400 mg. Persons with microfilaremia also
received additional DEC to complete a 14 day course
of treatment.
Indonesia: study area and subjects
This study was performed in the municipality of
Pekalongan, a city on the northern coast of central Java
that is endemic for bancroftian filariasis. Pekalongan’s
282,000 residents live in 47 villages/neighborhoods that
are served by 12 primary health centers (Puskesmas;
http://www.dinkesjatengprov.go.id/). The village of
Kertoharjo that was chosen for this study received 4
rounds of MDA with diethylcarbamazine plus albenda-
zole between 2011 and 2014. A survey in Kertoharjo in
2012 (12 months after the first round of MDA) found Mf
(by 60 μl thick smear) and CFA rates by Card Test of 2.2
and 4.1 %, respectively. The fourth round of MDA was
distributed in Kertoharjo in the summer of 2014, ap-
proximately 2 months prior to the current study, which
was performed in August-September 2014. There were
two components to the Kertoharjo study. A community
survey tested residents > 5 years of age in a convenience
sample of households. The second part of the Kertoharjo
study tested children ages 6 to 15 who attended schools
in the village. The school survey was conducted to in-
crease the number of school-aged children in the study.
This is because many parents were reluctant to wake
children for blood collection during the community sur-
vey, which was performed in the evening. As in Sri
Lanka, all persons with positive CFA tests were treated
with a single oral dose of (DEC) 6 mg/kg plus albenda-
zole 400 mg.
Blood collection, antigen and microfilaria testing
Washington University investigators trained staff in Sri
Lanka and Indonesia on standard operating procedures
for blood collection and antigen testing. Training in Sri
Lanka included laboratory testing of approximately 200
samples collected during a pilot study in Hill Side
Watta in Galle district. Blood samples for this pilot
study were collected in Ethylenediaminetetraacetic
acid (EDTA) coated blood collection tubes (Fisher
Scientific, Pittsburgh, PA), and the antigen tests were
performed in a laboratory the next morning. Results
from this pilot survey showed a much greater discord-
ance between the tests than expected, with more posi-
tives by FTS. Most people with discordant test results
with EDTA blood were negative by both tests when they
were retested in the field with finger prick blood accord-
ing to the manufacturer’s instructions, and this method
was used for the surveys in Unawatuna West, Matatogama,
and Pekalongan that are reported in this paper. The
Indonesian study was initiated without a pilot field study.
Blood was collected with sterile, single use, contact
activated BD-microtainer lancets (Fisher Scientific).
Community blood samples were collected between
16:00–23:00 h in Sri Lanka and between 10:00–22:00 h
in Indonesia. Barcode stickers were used to link CFA test
results with participants’ demographic records. Barcode
stickers were attached to FTS and Card tests, and the
stickers were used to secure FTS in their plastic boats.
Blood samples were applied to the two CFA tests ac-
cording to the manufacturer’s instructions. Test Strips
and Card Tests were read by different technicians. Test
results were recorded independently at 10 min, and re-
sults were verified by a third reader who served as a
supervisor. Test results were scored according to the in-
tensity of the test “T” line relative to that of control “C”
line as previously described [11]. Briefly, scores for both
tests were recorded as follows: 0, no T line visible; 1, T
line is weaker than the C line; 2, T line is equal to the C
line; 3, T line is stronger than the C line. The Sri Lanka
study also scored the tests at 30 min and at 12 h.
Persons with positive antigen tests at 10 min had
blood collected at night for Mf testing. Finger prick
blood samples were collected between the hours of
20:00 and 23:00 in Indonesia and between 21:00 and
23:00 in Sri Lanka. Three-line thick blood smears (a
total of 60 μl of blood per smear) were stained with
Giemsa and examined for Mf by microscopy. The Sri
Lanka study also used membrane filtration of 1 ml of
venous blood for Mf detection [14].
Data collection, management, and analysis
Demographic information (name, household, age, gen-
der, and documentation of informed consent) was re-
corded on preprinted paper forms. Identifying data,
specimen ID, FTS, and Card test results were linked
using barcode stickers, and results were entered into
Microsoft Excel files. Unique identifiers were removed
from data files prior to analysis. The Sri Lanka study also
collected household GPS coordinates with personal
digital assistants (PDA) (HP iPAQ 211, Hewlett Packard,
Palo Alto, CA). Locations were plotted using ArcGIS
10.2.1 (ESRI, Redlands, CA), and waypoints were color
coded to mark households with one or more positive fil-
arial antigen tests.
The software packages PASW Statistics 18 (SPSS, IBM
Corporation, Armonk, NY) and R 3.1.1. [15] were used
for data analysis. The Chi-square test was used to com-
pare results obtained with the two antigen tests. This
analysis and the calculation of % agreement between the
two antigen tests only considered samples with valid re-
sults for both tests. The Effect of age on CFA test results
was also assessed using a generalized linear model
(GLM) with a binomial family function that also consid-
ered gender [15]. Age was logx transformed for the
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Indonesia data to meet assumptions for normality. This
was not required for the Sri Lanka data. The Wilcoxon
signed rank test was used to assess the significance of
differences in test scores obtained by FTS and Card
Test.
Results and discussion
Results of CFA comparison studies in Sri Lanka
and Indonesia
Eight hundred fifty-five subjects (Age range 5–91,
median 35) from Unawatuna west and Matotagama,
Sri Lanka and 815 subjects (Age > 5–77, median 11)
in Pekalongan, Indonesia were enrolled in the test com-
parison studies. 491 of 815 (60 %) Indonesian study sub-
jects were school-aged children (Age 6–15). 43 % of
enrolled subjects were males in both countries.
Test results are summarized in Table 1. 852 subjects
in Sri Lanka and 782 subjects in Indonesia had valid re-
sults with both CFA tests, and these results were used
for the comparative analysis. There were very few invalid
tests in the Sri Lanka study (1 Card Test and 2 FTS). In
contrast, there were 4 invalid Card Tests and 33 (4.2 %
of the total) invalid FTS results in Indonesia. Invalid
FTS results in Indonesia were due to blood clotting in
the blood collection device or to too little blood collected
or applied to the Test Strip, both of which would de-
crease flow of serum on the Test Strips. Most of the in-
valid FTS results occurred in the first few days of the
study, and this problem decreased after the technicians
gained experience with the plastic blood collection de-
vices. Besides causing invalid test results, partial clotting
or incomplete flow could also reduce the sensitivity of
the FTS by reducing the volume of serum (FTS) or
plasma (Card Test) that flows across the “T” line. The
pilot study in Sri Lanka provided field training with both
tests, and this may account for the low rate of invalid
FTS and the lack of Card Test-positive/FTS-negative re-
sults in the Sri Lanka study.
Study personnel in both countries mentioned the
problem of securing the light weight FTS in plastic
holders, and they complained that it is more difficult to
label the thin plastic FTS compared to the Card Test. As
mentioned above, there is also a learning curve for use
of the plastic micropipettes that come with the FTS kits.
These factors make the FTS slightly more difficult to use
than the Card Test.
While almost all samples that were positive by Card
Test were also positive by FTS, many samples that were
negative by Card Test were positive by FTS. This finding
is illustrated in Fig. 1, which compares the distribution
of houses with residents with positive CFA tests by FTS
and Card Test. The FTS/Card Test ratio (the number of
positive FTS divided by the number of positive Card
Tests for people with valid results for both tests) was
2.33 in the Sri Lanka study but only 1.22 in Indonesia.
Exclusion of results for 3 samples with positive Card
Test and negative FTS results raises the Indonesian
FTS/Card Test ratio to 1.32.
Associations of age and gender with CFA test results
CFA rates differed by age and gender in the Sri Lanka
study. Antigen prevalence rates tended to increase with
age, and this trend was stronger for FTS results (Table 2).
Only 1 of 53 children less than 11 years of age (most of
them born after Sri Lanka’s MDA program was com-
pleted in 2006) had a positive CFA test result (by FTS
only). CFA rates were also higher in males than in fe-
males by FTS in Sri Lanka (31/359 or 8.7 % vs. 12/493
or 2.4 %, P < 0.05). The CFA rate by FTS was higher in
adults than in children (5.7 % in people with age > 15 vs.
1.5 % in those with ages 6–15, P <0.05). The same age
and gender trends were observed in the Indonesia study:
CFA rates by FTS were higher in males than in females
(31/332 or 9.3 % vs. 19/446 or 4.3 %, P <0.05), and rates
in adults (age > 15) were higher than rates in children
(10 % vs. 4 %, respectively, P <0.05). Higher CFA rates in
males in both study sites may be due to higher baseline
infection rates in males prior to MDA or to lower MDA
compliance in males. CFA rates in children < 11 years of
age were similar by both tests in the Indonesia study
(3.5 % by FTS and 3.2 % by Card Test). This result sug-
gests that a school-based transmission assessment sur-
vey in this area would have failed by FTS or by Card
Test.
We also tested the effect of age on antigenemia rates
using a GLM that controlled for the effect of gender.
Higher age was significantly associated with positive
CFA test results for both tests in both the Sri Lankan
Table 1 Cross-tabulation of filarial antigen test results obtained
by the Card Test and the Test Strip
Country No. tested
Card Test result
FTS result Positive Negative Totals
Sri Lanka 852 Positive 18 25 43
Negative 0 809 809
Totals 18 834 852
% Agreement; Kappa score (95 % CI): 97.07 %;
0.578 (0.430–0.725). Chi-square = P <0.0001
Indonesia 778 Positive 38 12 50
Negative 3 725 728
Totals 41 737 778
% Agreement; Kappa score (95 % CI): 98 %;
0.825 (0.739–0.912). Chi-square = P <0.0001
Results shown are for 852 and 778 blood samples from Sri Lanka and
Indonesia with valid results with both filarial antigen tests
FTS Filariasis Test Strip
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and in Indonesian study sites with P values that were no
higher than < 0.02 for all four comparisons.
Comparison of card test and FTS scores
FTS scores (based on the intensity of “T” lines) tended
to be higher than Card Test scores (Table 3). In the Sri
Lanka survey, the mean (SD) test scores for samples
with positive FTS or Card Test were 1.72 (0.79) and 0.67
(0.96), respectively (P < 0.0001). In Indonesia, the mean
(SD) scores for samples with positive FTS or Card Test
were 1.64 (0.87) vs. 0.98 (0.72), respectively (P <0.0001).
When combined data from both countries is considered,
most subjects with positive FTS and negative Card Test
results had FTS scores of 1 (30 of 37 or 81 %), and only
Fig. 1 The background map shows the location of Matotagama village (circle) in Matara district, Sri Lanka. The inset map on the left shows
households included in the survey. Red dots indicate households with one or more residents with positive Filariasis Test Strip (FTS) results where
all residents had negative Card Tests. Blue dots show households with residents who were positive for circulating filarial antigenemia (CFA) by
FTS and the Card Test. Green dots show houses with no positive CFA test results. All persons in this study site with positive Card Test results
were also positive by FTS
Table 2 Circulating filarial antigenemia test results by age as assessed in Sri Lanka and Indonesia
Sri Lanka Indonesia
Age (years) Test Strip Card Test Test Strip Card Test
POS / total % (95 CI) POS / total % (95 CI) POS / total % (95 CI) POS / total % (95 CI)
<11 1/53 1.9 (0.3–9.9) 0/53 0.0 (0–6.9) 12/353 3.4 (1.9–5.8) 11/353 3.1 (1.7–5.4)
11–20 4/172 2.3 (0.9–5.8) 0/172 0.0 (0–2.2) 8/126 6.3 (3.2–12.0) 5/126 4.0 (1.7–8.9)
21–30 6/125 4.8 (2.2–10.1) 4/125 3.2 (1.3–7.9) 10/75 13.3 (7.4–22.8) 8/75 10.7 (5.5–19.6)
31–40 9/154 5.8 (3.1–10.7) 4/154 2.6 (1.0–6.5) 9/88 10.2 (5.4–18.3) 7/88 8.0 (3.9–15.5)
41–50 5/142 3.5 (1.5–8.0) 2/142 1.4 (0.4–5.0) 2/70 2.9 (0.8–9.83) 2/70 2.9 (0.8–9.83)
51–60 8/113 7.1 (3.6–13.4) 4/113 3.5 (1.4–8.8) 8/53 15.1 (7.8–27.5) 7/53 13.2 (6.5–24.8)
≥61 10/93 10.8 (5.9–18.7) 4/93 4.3 (1.7–10.5) 1/13 7.7 (1.4–33.3) 1/13 7.7 (1.4–33.3)
Total 43/852 5.0 (3.7–6.7) 18/852 2.1 (1.3–3.3) 50/778 6.4 (4.9–8.3) 41/778 5.3 (3.9–7.0)
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15 of 45 (33 %) samples with FTS scores of 1 had posi-
tive Card Tests. On the other hand, 41 of 48 (85 %) of
samples with scores of 2 or 3 by FTS had positive Card
Test results.
CFA test result stability
Stability of CFA test results was assessed in the Sri
Lanka study. Tests that were negative at 10 min were
read again at 30 min and 12 h. More FTS turned
positive at both time points compared to Card Tests
(1.7 % vs. 0.5 % at 30 min, and 3.8 % vs. 1.4 % at
12 h, respectively). These results provide an indica-
tion of what to expect if there is a delay in reading
these CFA tests. While it is possible that some or all
of the delayed positive results were true positives,
both tests should be read at 10 min as recommended
by the manufacturer.
Microfilaremia test results
Night blood testing for Mf was performed for most of
the study participants who had positive CFA results by
either the Card Test or FTS. Six of 43 (14 %) Sri Lankan
subjects with positive FTS results had microfilaremia
(range 1–1245 Mf; mean ± SD = 276 ± 485 per ml) by
membrane filtration. All six of these subjects had FTS
scores ≥ 2. However, only 4 of 43 (9.3 %) of people with
positive FTS results had Mf by thick smear (range 2–45
Mf; mean ± SD = 13 ± 19 per 60 μl). Four of 18 (22 %)
people with positive Card Tests had Mf by both mem-
brane filtration and by thick smear. While all four people
with Mf by thick smear had positive Card Test and FTS
results, only one of two people with Mf by filter but not
by thick smear had a positive Card Test.
In the Indonesia study, 8 of 34 (23.5 %) participants
with positive FTS results were Mf positive by night blood
smear (range 2–52 Mf per 60 μl; mean ± SD = 5 ± 13). In
contrast, a higher proportion of people with positive
Card Tests were Mf positive (8 of 25, 32 %). All of the
Mf positive subjects were positive for CFA by both the
FTS and Card Test, but only 5 of 8 had FTS scores ≥ 2.
Membrane filtration was not performed in the Indonesia
study. These results show that only a minority of
people with positive CFA tests have microfilaremia
and that Mf rates for those with positive Card Tests
tend to be higher than rates in those with positive
FTS results.
Additional discussion points
This study has provided useful information on the per-
formance of the FTS and the Card Test in areas with
low residual LF infection rates and infection intensities
following multiple rounds of MDA. The finding that
CFA rates were higher by FTS than by Card test is con-
sistent with the known superior analytical sensitivity of
the FTS. We do not know why the difference in CFA
rates by FTS and Test Strip positivity was so much
higher in Sri Lanka than in Indonesia. It is interesting
that this difference was much more striking in adults
than in children.
This study has also confirmed the value of semi-
quantitative scoring for FTS and Card Test results. FTS
scores were significantly higher than Card Test scores in
both study sites. In addition, combined data from both
study sites showed that most people with microfilaremia
(11 of 14 or 79 %) had FTS scores ≥ 2.
The improved sensitivity of the FTS increases its value
for mapping LF endemicity, as illustrated in Fig. 1. The
FTS will also be superior to the Card Test for post-
MDA surveys of adults and for studies that assess the
macrofilaricidal effects of new treatments. Since CFA
rates by both tests were similar in children less than
11 years of age in both study sites, a switch from the
Card Test to the FTS should not dramatically affect
post-MDA transmission assessment survey (TAS) re-
sults, since those surveys sample young school aged
children.
Conclusions
Results from this study support the idea of using the
FTS instead of the Card Test in LF elimination pro-
grams. The smaller blood requirement (75 μl), lower
cost, and longer shelf life of the FTS also favor the
switch. It would be helpful if the FTS kits could be
modified to make them more user-friendly. As with any
new point of care test, technicians should be provided
with training and practical experience performing the
test before it is deployed in national surveys. Special
training materials might help to ease the transition from
the Card Test to the FTS.
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